Scientists from the United Kingdom may have identified several more environmental causes for cancer after evaluating the genetic data of over 12,000 cancer patients from National Health Service files.
GeoVax vaccine targeting virus in two places shows promise; virus may become resistant to antibody drugs
Antibody Studies, BNT162b2 (Pfizer and BioNTech), Cell, Clinical Trials, COVID-19 Studies, Delta Variant (B.1.617.2; India), Genetics, GlaxoSmithKline, Immunosuppression, Janssen COVID-19 Vaccine (J&J), Medical Journals, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Mutations, New England Journal of Medicine, Omicron (B.1.1.529) (South Africa), R&D, Researchers, SARS-CoV-2 spike protein, The Lancet, The Lancet Microbe, Vir BiotechnologyAn experimental vaccine developed by GeoVax Labs Inc. succeeded in promoting development of antibodies that target two different sites on the virus in a small pilot study and was advanced to mid-stage clinical trials, researchers reported.
COVID-19 patients who receive one of the few antibody treatments that works against the Omicron variant must be carefully monitored because after the drug is infused, the virus may mutate and become resistant to it, researchers warned after seeing such cases with Delta variant patients.
The World Health Organization’s chief scientist, Soumya Swaminathan, said on February 11 that the world was not yet at the end of the COVID-19 pandemic as there would be more coronavirus variants.
The newly discovered COVID-19 variant, dubbed IHU (also known as B.1.640.2), is the latest in a long string of variants as the SARS-CoV-2 virus inches closer to either becoming endemic or burning itself out.
Reata Pharmaceuticals Inc. announced the outcome of the U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting on bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome.
The U.S. Food and Drug Administration made the decision to grant Breakthrough Therapy Designation to Mirati Therapeutics’ adagrasib for the potential treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.
The U.S. Food and Drug Administration approved Genentech and Blueprint Medicines’ Gavreto (pralsetinib) as a treatment for adults and pediatric patients 12 and older who have been diagnosed with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).
A therapy jointly developed by Switzerland’s Roche Holding AG and Cambridge, Mass.-based Blueprint Medicines Corp. was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).
Bristol Myers Squibb announced that the Phase III IDHENTIFY trial of Idhifa (enasidenib) plus best supportive care compared to conventional care did not meet the primary endpoint of overall survival in relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation.
Research Roundup: Can Flu and Pneumonia Vaccines Prevent Alzheimer’s and More
Alzheimer's Association International Conference, Alzheimer’s disease, Brain Cells, Cells, Clinical Trials, Duke University, Flu Vaccines, Genes, Genetic Database, Genomes, Herpes, Microbiome, Mutations, Pneumonia Vaccines, R&D, Researchers, Scientific studiesA review of recently published scientific studies includes a look at the potential of using flu and pneumonia vaccines to decrease the risk of developing Alzheimer’s disease.